Upregulated Expression of
            <i>MTFR2</i>
            as a Novel Biomarker Predicts Poor Prognosis in Hepatocellular Carcinoma by Bioinformatics Analysis

Li, Dan; Ji, Yanmei; Guo, Jialong; Guo, Qiang

doi:10.2217/fon-2020-1160

Cited by 15 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the mechanism of m6A/m1A/m5C regulated genes in HCC progression remains to be confirmed in future studies. Currently, targeted therapy and immunotherapy are among the treatment options available to HCC patients (2,(35)(36)(37)(38). For example, PD-1 inhibitors are well tolerated by HCC patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma

Zhang

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

RNA modification of m6A/m5C/m1A contributes to the occurrence and development of cancer. Consequently, this study aimed to investigate the functions of m6A/m5C/m1A regulated genes in the prognosis and immune microenvironment of hepatocellular carcinoma (HCC). The expression levels of 45 m6A/m5C/m1A regulated genes in HCC tissues were determined. The functional mechanisms and protein–protein interaction network of m6A/m5C/m1A regulated genes were investigated. The Cancer Genome Atlas (TCGA) HCC gene set was categorized based on 45 m6A/m5C/m1A regulated genes, and survival analysis was used to determine the relationship between the overall survival of HCC patients in subgroups. Cox and least absolute shrinkage and selection operator (LASSO) regression analyses were used to construct the risk model and nomogram for m6A/m5C/m1A regulated genes. The relationships between m6A/m5C/m1A regulated gene subsets and risk model and immune cell infiltration were analyzed using CIBERSORT. m6A/m5C/m1A regulated genes were involved in mRNA and RNA modifications, mRNA and RNA methylation, mRNA and RNA stability, and other processes. There was a statistically significant difference between cluster1 and cluster2 groups of genes regulated by m6A/m5C/m1A. The prognosis of cluster1 patients was significantly better than that of cluster2 patients. There were statistically significant differences between the two cluster groups in terms of fustat status, grade, clinical stage, and T stage of HCC patients. The risk model comprised the overexpression of YBX1, ZC3H13, YTHDF1, TRMT10C, YTHDF2, RRP8, TRMT6, LRPPRC, and IGF2BP3, which contributed to the poor prognosis of HCC patients. The high-risk score was associated with prognosis, fustat status, grade, clinical stage, T stage, and M stage and was an independent risk factor for poor prognosis in HCC patients. High-risk score mechanisms included spliceosome, RNA degradation, and DNA replication, among others, and high-risk was closely related to stromal score, CD4 memory resting T cells, M0 macrophages, M1 macrophages, resting mast cells, CD4 memory activated T cells, and follicular helper T cells. In conclusion, the cluster subgroup and risk model of m6A/m5C/m1A regulated genes were associated with the poor prognosis and immune microenvironment in HCC and are expected to be the new tools for assessing the prognosis of HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Liver cancer is one of the most prevalent cancers worldwide. Hepatocellular carcinoma (HCC) accounts for approximately 80% of liver cancer (1,2). Recent studies have demonstrated that targeted therapy and immunotherapy significantly affect HCC patient survival (3)(4)(5)(6).…”

Section: Introductionmentioning

confidence: 99%

The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma

Zhang

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…KIF20A downregulation may decrease the proliferation and induce the G1 arrest of HCC cells [ 32 ]. CDCA8 is in relation to unfavorable stage and survival outcomes of HCC [ 33 ]. CDCA8 inhibition weakens HCC growth and stemness through restoring ATF3 and inactivating AKT/ β -catenin axis [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

Objective. Dysregulation of cell cycle progression (CCP) is one of the hallmarks of cancer. Here, our study is aimed at developing a CCP-derived gene signature for predicting high-risk population of hepatocellular carcinoma (HCC). Methods. Our study retrospectively analyzed the transcriptome profiling and clinical information of HCC patients from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) projects. Uni- and multivariate cox regression models were conducted for identifying which hallmarks of cancer were risk factors of HCC. CCP-derived gene signature was developed with LASSO method. The predictive efficacy was verified by ROC curves and subgroup analyses. A nomogram was then generated and validated by ROC, calibration, and decisive curves. Immune cell infiltration was estimated with ssGSEA method. Potential small molecular compounds were predicted via CTRP and CMap analyses. The response to chemotherapeutic agents was evaluated based on the GDSC project. Results. Among hallmarks of cancer, CCP was identified as a dominant risk factor for HCC prognosis. CCP-derived gene signature displayed the favorable predictive efficacy in HCC prognosis independent of other clinicopathological parameters. A nomogram was generated for optimizing risk stratification and quantifying risk evaluation. CCP-derived signature was in relation to immune cell infiltration, HLA, and immune checkpoint expression. Combining CTRP and CMap analyses, fluvastatin was identified as a promising therapeutic agent against HCC. Furthermore, CCP-derived signature might be applied for predicting the response to doxorubicin and gemcitabine. Conclusion. Collectively, CCP-derived gene signature was a promising marker in prediction of survival outcomes and therapeutic responses for HCC patients.

show abstract

“…Thus, exploring the underlying mechanism of the development of HCC is important for identifying early diagnostic biomarkers for HCC and for improving the prognosis of HCC. Although various studies have attempted to discover new biomarkers for predicting the prognosis of HCC or detecting early HCC, 16,17 these biomarkers lack effectiveness for HCC, and most studies have focused on whole-stage HCC.…”

Section: Discussionmentioning

confidence: 99%

PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma

Jiang¹,

Song²,

Pan³

et al. 2021

IJGM

View full text Add to dashboard Cite

Objective The occurrence and development of hepatocellular carcinoma (HCC) remain unclear. This study aimed to investigate potential diagnostic or prognostic markers for early HCC by applying bioinformatic analysis. Methods The gene expression profiles of early HCC and normal tissues from a TCGA dataset were used to identify differentially expressed genes (DEGs) and then analysed by weighted gene coexpression network analysis. The integrated genes were selected to construct the protein–protein interaction (PPI) network and determine the hub genes. The prognostic impact of the hub genes was then analysed. Results A total of 508 integrated genes were selected from the 615 DEGs and 8956 genes in the turquoise module. A PPI network was constructed, and the top 20 hub genes, including apolipoprotein A-IV (APOA4), fibrinogen gamma chain (FGG), vitamin K-dependent protein Z (PROZ), secreted phosphoprotein 24 (SPP2) and fetuin-B (FETUB), were identified. Only PROZ was significantly associated with the prognosis of early HCC. Conclusion In this study, we demonstrated that the expression of PROZ was decreased in early HCC compared with normal liver controls, and low PROZ expression might result in poor overall survival of early HCC.

show abstract

Upregulated Expression of MTFR2 as a Novel Biomarker Predicts Poor Prognosis in Hepatocellular Carcinoma by Bioinformatics Analysis

Cited by 15 publications

References 27 publications

The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma

The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma

A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma

PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma

Contact Info

Product

Resources

About